BRAF V600 Mutation Clinical Trials

21 clinical trials for BRAF V600 Mutation across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas — RECRUITING · PHASE2
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies — RECRUITING · PHASE1
• Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance — RECRUITING
• Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma — RECRUITING · PHASE1
• A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) — RECRUITING
• Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC — RECRUITING · PHASE2
• Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis — ACTIVE_NOT_RECRUITING · PHASE2
• A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients — COMPLETED
• Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer — COMPLETED · PHASE2
• A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) — COMPLETED
• XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation — NOT_YET_RECRUITING · PHASE1
• A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors — TERMINATED · PHASE1
• Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations — COMPLETED · PHASE1
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors — TERMINATED · PHASE1
• Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations — NOT_YET_RECRUITING · PHASE2
• Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases — TERMINATED · PHASE2
• Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma — WITHDRAWN · PHASE1
• BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation — COMPLETED
• To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. — OTHER · PHASE2
• Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations — OTHER · PHASE1
• Advanced Melanoma in Russian Experience — COMPLETED

Refine this search